dndn up 5.6% on volume of 12 million, page-9

As i've said for a long time i really think people should distance themselves from the DNDN link (or comparisons) as you only build the stock up to suffer the downside implications when DNDN tumbles. The biggest downside for any drug either approved or in development aside from faulting in trials or being pulled from market due to adverse effects after it's approved is when rivals step into the space & compete with the druhs market. J&J has had very interesting developments with Zytiga in recent weeks & while the final outcome might still be some time away it's potentially got a lead weight to drop on Provenge - i really don't think anyone wants PRR to be so closely linked with DNDN's share price peformance if Zytiga gets approved for expanded use by the FDA later this year.